This is the authors' abstract. We don't add key points for this paper.
A new, competitive, nonpeptide cholecystokinin (CCK) antagonist, asperlicin, was isolated from the fungus Aspergillus alliaceus. The compound has 300 to 400 times the affinity for pancreatic, ileal, and gallbladder CCK receptors than proglumide, a standard agent of this class. Moreover, asperlicin is highly selective for peripheral CCK receptors relative to brain CCK and gastrin receptors. Since asperlicin also exhibits long-lasting CCK antagonist activity in vivo, it should provide a valuable tool for investigating the physiological and pharmacological actions of CCK.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chang et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: